Last reviewed · How we verify
Quetiapine, Risperidone, Fluphenazine
These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood.
These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Acute agitation or psychosis.
At a glance
| Generic name | Quetiapine, Risperidone, Fluphenazine |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Drug class | Antipsychotic (atypical and typical) |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Quetiapine, risperidone, and fluphenazine are antipsychotic medications that work primarily by antagonizing dopamine D2 receptors in the brain, which reduces positive symptoms of psychosis such as hallucinations and delusions. Quetiapine and risperidone (atypical antipsychotics) also block serotonin 5-HT2A receptors, which may contribute to mood stabilization and reduced extrapyramidal side effects compared to fluphenazine (a typical antipsychotic). The combination or comparative study of these agents likely aims to optimize efficacy and tolerability profiles.
Approved indications
- Schizophrenia
- Bipolar disorder
- Acute agitation or psychosis
Common side effects
- Sedation
- Weight gain
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Orthostatic hypotension
- Metabolic syndrome (hyperglycemia, dyslipidemia)
- Prolactin elevation
Key clinical trials
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia (PHASE3)
- Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Reducing Antipsychotic-Induced Weight Gain in Children With Metformin (PHASE1)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Switching Medication to Treat Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |